ASSESSMENT OF POTENTIAL COCAINE TREATMENT MEDICATIONS

潜在可卡因治疗药物的评估

• 批准号: 6159655
• 负责人: NANCY K MELO
• 金额: $ 79.92万
• 依托单位: MCLEAN HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-30 至 2001-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6159655
• 关键词: Primates; cocaine; drug abuse chemotherapy; drug addiction; drug addiction antagonist; drug adverse effect; drug screening /evaluation; nonhuman therapy evaluation

This represents a competitive renewal of NIDA contract N01DA-2-9306, entitled "Assessment of Potential Cocaine Treatment Medications in Monkeys". The primary objective of the research and development project described herein is to screen potential pharmacotherapies for cocaine abuse by evaluating compounds in drug discrimination and self- administration paradigms in nonhuman primates. These tests have been selected by NIDA's medications Development Division (MDD) because they are believed to represent model systems that are predictive of clinical efficacy of pharmacotherapies for cocaine dependence. Results from this project will be utilized by NIDA's MDD to make decisions regarding selection of compounds for further development (i.e., toxicological evaluation and initial clinical evaluation) as pharmacotherapies for cocaine dependence. In brief, the objectives of this contract are to determine the effects of test compounds in the following paradigms: (1) drug discrimination test in nonhuman primates when tested alone or in combination with cocaine (i.e., a preclinical evaluation of the test compound's subjective profile), and (2) self-administration test in nonhuman primates when tested for ability to block cocaine self-administration or to be directly self- administered (i.e., a preclinical evaluation of the reinforcing properties and potential for abuse). The anticipated end results of this contract are written reports detailing study findings.

这代表了NIDA合同N 01 DA-2-9306的竞争性续约， 题为“评估潜在的可卡因治疗药物， 猴子”。 研究和开发的主要目标 本文描述的项目是筛选潜在的药物治疗， 可卡因滥用通过评估化合物在药物辨别和自我 非人类灵长类动物的管理模式。 这些检测 被NIDA的药物开发部门（MDD）选中，因为他们 被认为代表了预测临床疾病的模型系统， 药物治疗对可卡因依赖的疗效。 结果从这个 NIDA的MDD将利用该项目做出有关 用于进一步开发的化合物的选择（即，毒理学 评价和初步临床评价）作为药物治疗， 可卡因依赖 简而言之，本合同的目的是确定 在以下范例中测试化合物：（1）药物辨别测试 在非人灵长类动物中，当单独或与可卡因组合测试时， (i.e.,测试化合物的主观特征的临床前评价）， 和（2）非人灵长类动物的自我给药试验， 阻止可卡因自我给药或直接自我给药的能力， 施用（即，加强性能的临床前评价 可能被滥用）。 本合同的预期最终结果 是详细说明研究结果的书面报告。